Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc.AMRX · Entity 820 | Director | May 06, 2019 | May 08, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Amneal Pharmaceuticals, Inc.
Report date May 06, 2019 · Filed May 08, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 96,582 |
Reported balance
After 2019-05-08 transaction · row 1
1 source rowRow 1 · 2019-05-08 · Exercise / conversion · Acquired 6,107 · Balance 96,582 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $14.05 · Expires 2029-05-06 | Direct | 28,044 |
Reported balance
After 2019-05-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-05-06 · Grant · Acquired 28,044 · Balance 28,044 F2: The option vests on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 6,459 |
Reported balance
After 2019-05-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-05-06 · Grant · Acquired 6,459 · Balance 6,459 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3: Restricted stock units vest on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Restricted stock units have no expiration date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-05-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-05-08 · Exercise / conversion · Disposed 6,107 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4: On May 7, 2018, the reporting person was granted 6,107 restricted stock units vesting on May 8, 2019. |
| Class A Common StockSEC Table I · non-derivative | IndirectBy the Robert L. Burr IRA Account | 6,057 |
Reported balance
Holding disclosure · report date 2019-05-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 6,057 |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2: The option vests on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant.
F3: Restricted stock units vest on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Restricted stock units have no expiration date.
F4: On May 7, 2018, the reporting person was granted 6,107 restricted stock units vesting on May 8, 2019.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Impax Laboratories, LLC
Report date May 04, 2018 · Filed May 08, 2018
Section 16 reporting ended · disclosed 2018-05-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 1
1 source rowRow 1 · 2018-05-04 · Disposition to issuer · Disposed 55,067 · Balance 0 F1: Common Stock disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017 (the "BCA"), by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017, according to which each share of Common Stock held by the reporting person was converted into the right to receive one share of Class A common stock of Holdco ("Class A Common Stock"). |
| Common StockSEC Table I · non-derivative | IndirectBy Robert L. Burr IRA Account | 0 |
Reported balance
After 2018-05-04 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2018-05-04 · Disposition to issuer · Disposed 6,057 · Balance 0 F1: Common Stock disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017 (the "BCA"), by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017, according to which each share of Common Stock held by the reporting person was converted into the right to receive one share of Class A common stock of Holdco ("Class A Common Stock"). |
| Restricted Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 3
1 source rowRow 3 · 2018-05-04 · Disposition to issuer · Disposed 5,408 · Balance 0 F2: Shares of restricted common stock disposed of pursuant to the terms of the BCA, according to which each share of restricted stock held by the reporting person fully vested and was exchanged for one share of Class A Common Stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.40 · Expires 2027-05-16 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-05-04 · Disposition to issuer · Disposed 10,575 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.33 · Expires 2026-05-17 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-05-04 · Disposition to issuer · Disposed 10,575 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.85 · Expires 2025-05-12 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-05-04 · Disposition to issuer · Disposed 7,300 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.24 · Expires 2024-05-14 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-05-04 · Disposition to issuer · Disposed 11,500 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.99 · Expires 2023-05-15 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-05-04 · Disposition to issuer · Disposed 12,000 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.90 · Expires 2022-05-23 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-05-04 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.97 · Expires 2021-05-11 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2018-05-04 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.30 · Expires 2020-05-26 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2018-05-04 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.55 · Expires 2019-05-20 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2018-05-04 · Disposition to issuer · Disposed 30,000 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Common Stock disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017 (the "BCA"), by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017, according to which each share of Common Stock held by the reporting person was converted into the right to receive one share of Class A common stock of Holdco ("Class A Common Stock").
F2: Shares of restricted common stock disposed of pursuant to the terms of the BCA, according to which each share of restricted stock held by the reporting person fully vested and was exchanged for one share of Class A Common Stock.
F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 08, 2019 Filed May 8, 2019 21:47 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 6,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001723128-19-000069 · wf-form4_155735204317594.xml · derivative · entry 5 BURR ROBERT L · CIK 0001245188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 6,107 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On May 7, 2018, the reporting person was granted 6,107 restricted stock units vesting on May 8, 2019. F4 · derivative.expiration_date: On May 7, 2018, the reporting person was granted 6,107 restricted stock units vesting on May 8, 2019. Read SEC document |
| May 08, 2019 Filed May 8, 2019 21:47 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 6,107 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001723128-19-000069 · wf-form4_155735204317594.xml · nonDerivative · entry 1 BURR ROBERT L · CIK 0001245188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,582 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| May 06, 2019 Filed May 8, 2019 21:47 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 6,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001723128-19-000069 · wf-form4_155735204317594.xml · derivative · entry 4 BURR ROBERT L · CIK 0001245188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,459 Underlying: Class A Common Stock · 6,459 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Restricted stock units have no expiration date. F3 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Restricted stock units have no expiration date. Read SEC document |
| May 06, 2019 Filed May 8, 2019 21:47 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 28,044 | $0.00 Strike: $14.05 | $0.00 |
DisclosureSEC source: 0001723128-19-000069 · wf-form4_155735204317594.xml · derivative · entry 3 BURR ROBERT L · CIK 0001245188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,044 Underlying: Class A Common Stock · 28,044 shares Expires 2029-05-06 F2 · derivative.exercise_date: The option vests on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document |
| January 15, 2019 Filed Jan 16, 2019 22:16 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionStock Option · Derivative | 30,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001723128-19-000013 · wf-form4_154767697362446.xml · derivative · entry 3 BURR ROBERT L · CIK 0001245188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 30,000 shares Expires 2019-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is vested and currently exercisable. Read SEC document |
| January 15, 2019 Filed Jan 16, 2019 22:16 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 30,000 | $6.55 | $196,500.00 |
DisclosureSEC source: 0001723128-19-000013 · wf-form4_154767697362446.xml · nonDerivative · entry 1 BURR ROBERT L · CIK 0001245188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2018 Filed May 8, 2018 23:23 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 6,107 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-011945 · doc4.xml · derivative · entry 13 BURR ROBERT L · CIK 0001245188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,107 Underlying: Class A Common Stock · 6,107 shares Expires not disclosed F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F7 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on May 07, 2019 and have no expiration date. F7 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on May 07, 2019 and have no expiration date. Read SEC document |
| May 07, 2018 Filed May 8, 2018 23:23 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 24,977 | $0.00 Strike: $15.01 | $0.00 |
DisclosureSEC source: 0000899243-18-011945 · doc4.xml · derivative · entry 12 BURR ROBERT L · CIK 0001245188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,977 Underlying: Class A Common Stock · 24,977 shares Expires 2028-05-07 F5 · derivative.exercise_date: The option vests in four equal annual installments beginning on May 07, 2019. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:19 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerStock Option (Right to Buy) · Derivative | 30,000 | Not disclosed Strike: $6.55 | Not disclosed |
DisclosureSEC source: 0001003642-18-000083 · wf-form4_152581074184262.xml · derivative · entry 12 BURR ROBERT L · CIK 0001245188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2019-05-20 F3 · shares: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · price: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · derivative.exercise_date: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:19 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $20.30 | Not disclosed |
DisclosureSEC source: 0001003642-18-000083 · wf-form4_152581074184262.xml · derivative · entry 11 BURR ROBERT L · CIK 0001245188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2020-05-26 F3 · shares: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · price: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · derivative.exercise_date: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:19 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $27.97 | Not disclosed |
DisclosureSEC source: 0001003642-18-000083 · wf-form4_152581074184262.xml · derivative · entry 10 BURR ROBERT L · CIK 0001245188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2021-05-11 F3 · shares: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · price: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · derivative.exercise_date: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:19 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $20.90 | Not disclosed |
DisclosureSEC source: 0001003642-18-000083 · wf-form4_152581074184262.xml · derivative · entry 9 BURR ROBERT L · CIK 0001245188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2022-05-23 F3 · shares: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · price: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · derivative.exercise_date: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:19 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,000 | Not disclosed Strike: $17.99 | Not disclosed |
DisclosureSEC source: 0001003642-18-000083 · wf-form4_152581074184262.xml · derivative · entry 8 BURR ROBERT L · CIK 0001245188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2023-05-15 F3 · shares: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · price: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · derivative.exercise_date: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:19 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerStock Option (Right to Buy) · Derivative | 11,500 | Not disclosed Strike: $25.24 | Not disclosed |
DisclosureSEC source: 0001003642-18-000083 · wf-form4_152581074184262.xml · derivative · entry 7 BURR ROBERT L · CIK 0001245188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,500 shares Expires 2024-05-14 F3 · shares: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · price: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · derivative.exercise_date: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:19 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,300 | Not disclosed Strike: $44.85 | Not disclosed |
DisclosureSEC source: 0001003642-18-000083 · wf-form4_152581074184262.xml · derivative · entry 6 BURR ROBERT L · CIK 0001245188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,300 shares Expires 2025-05-12 F3 · shares: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · price: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · derivative.exercise_date: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:19 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,575 | Not disclosed Strike: $30.33 | Not disclosed |
DisclosureSEC source: 0001003642-18-000083 · wf-form4_152581074184262.xml · derivative · entry 5 BURR ROBERT L · CIK 0001245188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,575 shares Expires 2026-05-17 F3 · shares: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · price: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · derivative.exercise_date: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:19 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,575 | Not disclosed Strike: $16.40 | Not disclosed |
DisclosureSEC source: 0001003642-18-000083 · wf-form4_152581074184262.xml · derivative · entry 4 BURR ROBERT L · CIK 0001245188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,575 shares Expires 2027-05-16 F3 · shares: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · price: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · derivative.exercise_date: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:19 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerRestricted Common Stock | 5,408 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001003642-18-000083 · wf-form4_152581074184262.xml · nonDerivative · entry 3 BURR ROBERT L · CIK 0001245188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · shares: Shares of restricted common stock disposed of pursuant to the terms of the BCA, according to which each share of restricted stock held by the reporting person fully vested and was exchanged for one share of Class A Common Stock. F2 · price: Shares of restricted common stock disposed of pursuant to the terms of the BCA, according to which each share of restricted stock held by the reporting person fully vested and was exchanged for one share of Class A Common Stock. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:19 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerCommon Stock | 6,057 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001003642-18-000083 · wf-form4_152581074184262.xml · nonDerivative · entry 2 BURR ROBERT L · CIK 0001245188 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Robert L. Burr IRA Account Disclosed balance after: 0 F1 · shares: Common Stock disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017 (the "BCA"), by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017, according to which each share of Common Stock held by the reporting person was converted into the right to receive one share of Class A common stock of Holdco ("Class A Common Stock"). F1 · price: Common Stock disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017 (the "BCA"), by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017, according to which each share of Common Stock held by the reporting person was converted into the right to receive one share of Class A common stock of Holdco ("Class A Common Stock"). Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:19 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerCommon Stock | 55,067 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001003642-18-000083 · wf-form4_152581074184262.xml · nonDerivative · entry 1 BURR ROBERT L · CIK 0001245188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Common Stock disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017 (the "BCA"), by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017, according to which each share of Common Stock held by the reporting person was converted into the right to receive one share of Class A common stock of Holdco ("Class A Common Stock"). F1 · price: Common Stock disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017 (the "BCA"), by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017, according to which each share of Common Stock held by the reporting person was converted into the right to receive one share of Class A common stock of Holdco ("Class A Common Stock"). Read SEC document |
| May 04, 2018 Filed May 8, 2018 23:23 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 30,000 | Not disclosed Strike: $6.55 | Not disclosed |
DisclosureSEC source: 0000899243-18-011945 · doc4.xml · derivative · entry 11 BURR ROBERT L · CIK 0001245188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Class A Common Stock · 30,000 shares Expires 2019-05-20 F4 · price: Received pursuant to the BCA in exchange for an option to purchase an equal number of shares of Impax common stock. F3 · derivative.exercise_date: The option is vested and currently exercisable. Read SEC document |
| May 04, 2018 Filed May 8, 2018 23:23 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 10,000 | Not disclosed Strike: $20.30 | Not disclosed |
DisclosureSEC source: 0000899243-18-011945 · doc4.xml · derivative · entry 10 BURR ROBERT L · CIK 0001245188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Class A Common Stock · 10,000 shares Expires 2020-05-26 F4 · price: Received pursuant to the BCA in exchange for an option to purchase an equal number of shares of Impax common stock. F3 · derivative.exercise_date: The option is vested and currently exercisable. Read SEC document |
| May 04, 2018 Filed May 8, 2018 23:23 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 10,000 | Not disclosed Strike: $27.97 | Not disclosed |
DisclosureSEC source: 0000899243-18-011945 · doc4.xml · derivative · entry 9 BURR ROBERT L · CIK 0001245188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Class A Common Stock · 10,000 shares Expires 2021-05-11 F4 · price: Received pursuant to the BCA in exchange for an option to purchase an equal number of shares of Impax common stock. F3 · derivative.exercise_date: The option is vested and currently exercisable. Read SEC document |
| May 04, 2018 Filed May 8, 2018 23:23 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 10,000 | Not disclosed Strike: $20.90 | Not disclosed |
DisclosureSEC source: 0000899243-18-011945 · doc4.xml · derivative · entry 8 BURR ROBERT L · CIK 0001245188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Class A Common Stock · 10,000 shares Expires 2022-05-23 F4 · price: Received pursuant to the BCA in exchange for an option to purchase an equal number of shares of Impax common stock. F3 · derivative.exercise_date: The option is vested and currently exercisable. Read SEC document |
| May 04, 2018 Filed May 8, 2018 23:23 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 12,000 | Not disclosed Strike: $17.99 | Not disclosed |
DisclosureSEC source: 0000899243-18-011945 · doc4.xml · derivative · entry 7 BURR ROBERT L · CIK 0001245188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Class A Common Stock · 12,000 shares Expires 2023-05-15 F4 · price: Received pursuant to the BCA in exchange for an option to purchase an equal number of shares of Impax common stock. F3 · derivative.exercise_date: The option is vested and currently exercisable. Read SEC document |
| May 04, 2018 Filed May 8, 2018 23:23 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 11,500 | Not disclosed Strike: $25.24 | Not disclosed |
DisclosureSEC source: 0000899243-18-011945 · doc4.xml · derivative · entry 6 BURR ROBERT L · CIK 0001245188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Underlying: Class A Common Stock · 11,500 shares Expires 2024-05-14 F4 · price: Received pursuant to the BCA in exchange for an option to purchase an equal number of shares of Impax common stock. F3 · derivative.exercise_date: The option is vested and currently exercisable. Read SEC document |
| May 04, 2018 Filed May 8, 2018 23:23 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 7,300 | Not disclosed Strike: $44.85 | Not disclosed |
DisclosureSEC source: 0000899243-18-011945 · doc4.xml · derivative · entry 5 BURR ROBERT L · CIK 0001245188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,300 Underlying: Class A Common Stock · 7,300 shares Expires 2025-05-12 F4 · price: Received pursuant to the BCA in exchange for an option to purchase an equal number of shares of Impax common stock. F3 · derivative.exercise_date: The option is vested and currently exercisable. Read SEC document |
| May 04, 2018 Filed May 8, 2018 23:23 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 10,575 | Not disclosed Strike: $30.33 | Not disclosed |
DisclosureSEC source: 0000899243-18-011945 · doc4.xml · derivative · entry 4 BURR ROBERT L · CIK 0001245188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,575 Underlying: Class A Common Stock · 10,575 shares Expires 2026-05-17 F4 · price: Received pursuant to the BCA in exchange for an option to purchase an equal number of shares of Impax common stock. F3 · derivative.exercise_date: The option is vested and currently exercisable. Read SEC document |
| May 04, 2018 Filed May 8, 2018 23:23 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 10,575 | Not disclosed Strike: $16.40 | Not disclosed |
DisclosureSEC source: 0000899243-18-011945 · doc4.xml · derivative · entry 3 BURR ROBERT L · CIK 0001245188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,575 Underlying: Class A Common Stock · 10,575 shares Expires 2027-05-16 F4 · price: Received pursuant to the BCA in exchange for an option to purchase an equal number of shares of Impax common stock. F3 · derivative.exercise_date: The option is vested and currently exercisable. Read SEC document |
| May 04, 2018 Filed May 8, 2018 23:23 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantClass A Common Stock | 6,057 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-011945 · doc4.xml · nonDerivative · entry 2 BURR ROBERT L · CIK 0001245188 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Robert L. Burr IRA Account Disclosed balance after: 6,057 F2 · price: Received in exchange for 6,057 shares of Impax common stock pursuant to the BCA. Read SEC document |
| May 04, 2018 Filed May 8, 2018 23:23 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantClass A Common Stock | 60,475 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-011945 · doc4.xml · nonDerivative · entry 1 BURR ROBERT L · CIK 0001245188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,475 F1 · price: Received in exchange for 60,475 shares of Impax Laboratories, Inc. ("Impax") common stock pursuant to the Business Combination Agreement, dated as of October 17, 2017, among Impax, Amneal Pharmaceuticals LLC, Atlas Holdings, Inc. and K2 Merger Sub Corporation (as amended, the "BCA"). Read SEC document |
| May 16, 2017 Filed May 17, 2017 15:46 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | GrantStock Option (Right-to-Buy) · Derivative | 10,575 | $0.00 Strike: $16.40 | $0.00 |
DisclosureSEC source: 0001003642-17-000049 · wf-form4_149505035928438.xml · derivative · entry 3 BURR ROBERT L · CIK 0001245188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,575 Underlying: Common Stock · 10,575 shares Expires 2027-05-16 F1 · derivative.exercise_date: The option fully vests on the earlier of (i) May 16, 2018 which is the first anniversary of the date of grant and (ii) one day before the date of the Company's next annual meeting of stockholders. Read SEC document |
| May 16, 2017 Filed May 17, 2017 15:46 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | GrantCommon Stock | 4,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001003642-17-000049 · wf-form4_149505035928438.xml · nonDerivative · entry 1 BURR ROBERT L · CIK 0001245188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,475 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.